Valeo Pharma Inc.

TSX:VPH Stock Report

Market Cap: CA$4.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Valeo Pharma Future Growth

Future criteria checks 2/6

Valeo Pharma is forecast to grow revenue at 20.9% per annum. EPS is expected to grow by 64.2% per annum.

Key information

n/a

Earnings growth rate

64.2%

EPS growth rate

Pharmaceuticals earnings growth65.0%
Revenue growth rate20.9%
Future return on equityn/a
Analyst coverage

Low

Last updated17 Jun 2024

Recent future growth updates

Recent updates

Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost

Jun 14
Market Might Still Lack Some Conviction On Valeo Pharma Inc. (TSE:VPH) Even After 55% Share Price Boost

Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower

Apr 20
Market Cool On Valeo Pharma Inc.'s (TSE:VPH) Revenues Pushing Shares 31% Lower

Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing

Mar 02
Valeo Pharma Inc. (TSE:VPH) Stocks Pounded By 33% But Not Lagging Industry On Growth Or Pricing

Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump

Jan 17
Investors Still Aren't Entirely Convinced By Valeo Pharma Inc.'s (TSE:VPH) Revenues Despite 68% Price Jump

Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%

Jun 08
Valeo Pharma Inc. (TSE:VPH) Might Not Be As Mispriced As It Looks After Plunging 29%

Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

Jun 24
Analysts Have Just Cut Their Valeo Pharma Inc. (TSE:VPH) Revenue Estimates By 24%

Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

Jun 17
Earnings Update: Valeo Pharma Inc. (TSE:VPH) Just Reported And Analysts Are Trimming Their Forecasts

Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?

Feb 08
Have Insiders Been Buying Valeo Pharma Inc. (CSE:VPH) Shares This Year?

Earnings and Revenue Growth Forecasts

TSX:VPH - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
10/31/202570N/AN/AN/A1
10/31/202458N/AN/AN/A1
7/31/202453-32-7-4N/A
4/30/202455-30-10-6N/A
1/31/202454-28-8-3N/A
10/31/202354-28-21-16N/A
7/31/202353-28-20-24N/A
4/30/202345-27-32-25N/A
1/31/202337-26-37-31N/A
10/31/202228-26-35-29N/A
7/31/202218-24-33-20N/A
4/30/202218-22-25-23N/A
1/31/202216-18-22-19N/A
10/31/202114-14-16-12N/A
7/31/202112-9-14-12N/A
4/30/20218-7-10-7N/A
1/31/20218-5-8-6N/A
10/31/20207-5-7-5N/A
7/31/20207-4-5-4N/A
4/30/20208-2-5-4N/A
1/31/20206-4-5-4N/A
10/31/20197-4-3-2N/A
7/31/20197-3-3-2N/A
4/30/20197-3-2-2N/A
1/31/20196-3-2-1N/A
10/31/20184-2-2-1N/A
7/31/20183-3-1-1N/A
10/31/20171-4N/A-1N/A
10/31/20161-1N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VPH's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if VPH's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if VPH's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VPH's revenue (20.9% per year) is forecast to grow faster than the Canadian market (7.2% per year).

High Growth Revenue: VPH's revenue (20.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VPH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/13 13:28
End of Day Share Price 2024/10/01 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neil LinsdelliA Capital Markets
Chelsea StellickiA Capital Markets
Scott McAuleyParadigm Capital, Inc.